Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
CanBas’ CBP501 Receives Orphan Drug Designation from US FDA
The drug discovery venture CanBas Co., Ltd. announced on January 4 that the US FDA has granted orphan drug designation to the anticancer agent CBP501 for use in combination with cisplatin and pemetrexed for the treatment of patients with mesothelioma.…
To read the full story
BUSINESS
- Middle East Turmoil Raises Fears over API Shipments as Key Airports Shut
March 3, 2026
- Ono, AstraZeneca to End Japan Co-Promotion of Forxiga
March 2, 2026
- Enhertu Filed in Japan as Adjuvant Therapy for Early Breast Cancer
March 2, 2026
- Shionogi, Torii File Lotion Form of Corectim in Japan
March 2, 2026
- Arcalis Completes mRNA Drug Facility, Establishes End-to-End CDMO Platform
March 2, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…